Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
G1 Therapeutics Inc (NASDAQ: GTHX) closed the day trading at $4.11 down -1.44% from the previous closing price of $4.17. In other words, the price has decreased by -$1.44 from its previous closing price. On the day, 0.73 million shares were traded. GTHX stock price reached its highest trading level at $4.305 during the session, while it also had its lowest trading level at $3.97.
Ratios:
For a better understanding of GTHX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.45 and its Current Ratio is at 3.87. In the meantime, Its Debt-to-Equity ratio is 1.62 whereas as Long-Term Debt/Eq ratio is at 1.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 30, 2023, Upgraded its rating to Neutral and sets its target price to $10 from $7 previously.
On January 03, 2023, Needham reiterated its Buy rating and also upped its target price recommendation from $32 to $31.
JP Morgan Downgraded its Neutral to Underweight on November 04, 2021, whereas the target price for the stock was revised from $20 to $19.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 18 ’24 when Umstead John W. V sold 6,547 shares for $3.02 per share. The transaction valued at 19,752 led to the insider holds 123,896 shares of the business.
Malik Rajesh sold 28,600 shares of GTHX for $132,143 on Feb 12 ’24. The Chief Medical Officer now owns 169,938 shares after completing the transaction at $4.62 per share. On Jan 04 ’24, another insider, MURDOCK TERRY L, who serves as the Chief Operating Officer of the company, sold 721 shares for $2.94 each. As a result, the insider received 2,121 and left with 103,638 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GTHX now has a Market Capitalization of 214539536 and an Enterprise Value of 189556512. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.60 while its Price-to-Book (P/B) ratio in mrq is 6.03. Its current Enterprise Value per Revenue stands at 2.297 whereas that against EBITDA is -4.859.
Stock Price History:
Over the past 52 weeks, GTHX has reached a high of $5.00, while it has fallen to a 52-week low of $1.08. The 50-Day Moving Average of the stock is 11.37%, while the 200-Day Moving Average is calculated to be 59.93%.
Shares Statistics:
Over the past 3-months, GTHX traded about 1.34M shares per day on average, while over the past 10 days, GTHX traded about 714010 shares per day. A total of 51.93M shares are outstanding, with a floating share count of 42.38M. Insiders hold about 18.81% of the company’s shares, while institutions hold 24.10% stake in the company. Shares short for GTHX as of 1711584000 were 2757220 with a Short Ratio of 2.06, compared to 1709164800 on 2911939. Therefore, it implies a Short% of Shares Outstanding of 2757220 and a Short% of Float of 5.33.
Earnings Estimates
Investors are keenly observing as G1 Therapeutics, Inc. analysts analyze and rate the current performance of G1 Therapeutics Inc (GTHX) in the stock market.The consensus estimate for the next quarter is $67.00, with high estimates of $4.03 and low estimates of $9.35.
